The PI3Kα Inhibitor Alpelisib Has Activity in PIK3CA-altered Tumors

    Cancer Discovery
    |February 18, 2018
    PubMed

    Insights

    The PI3Kα inhibitor alpelisib demonstrated a 58.2% disease control rate in solid tumors with PIK3CA alterations. This finding highlights alpelisib

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • Solid tumors frequently harbor PIK3CA alterations.
    • PI3Kα is a key driver in various cancers.
    • Targeting PI3Kα offers a potential therapeutic strategy.

    Discussion:

    • Alpelisib targets the PI3Kα pathway.
    • The study evaluated alpelisib in PIK3CA-altered solid tumors.
    • Disease control rate (DCR) is a measure of treatment efficacy.

    Key Insights:

    • Alpelisib achieved a 58.2% DCR in this patient cohort.
    • This indicates significant clinical activity of alpelisib.
    • PIK3CA alteration status is a predictive biomarker.

    Outlook:

    • Further investigation of alpelisib in specific solid tumor types is warranted.
    • Combination therapies may enhance efficacy.
    • Alpelisib represents a promising targeted therapy for PIK3CA-mutated cancers.

    Related Concept Videos

    Eukaryotic Transcription Inhibitors01:52

    Eukaryotic Transcription Inhibitors

    Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
    Eukaryotic transcription inhibitors usually contain two distinct domains, a...
    11.1K
    Alterations in Respiration II01:30

    Alterations in Respiration II

    There are numerous types of normal and abnormal respiration. Based on ventilatory movements, breathing patterns are classified as regular, deep, or shallow. Examples include Biot's breathing, Cheyne-Stokes respiration, Kussmaul's breathing, hyperventilation, and hypoventilation. Each pattern is clinically significant and aids in evaluating patients.
    In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
    1.9K
    Altered States of Awareness01:06

    Altered States of Awareness

    Altered states of consciousness represent significant deviations from one's normal mental state. These deviations can range from subtle changes in awareness to profound transformations in perception, thought processes, and sensory experiences. Altered states of consciousness can be triggered by various factors, including drug use, meditation, hypnosis, illness, or even intense fatigue.
    The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
    1.2K
    Alterations in Blood Pressure01:30

    Alterations in Blood Pressure

    Alterations in blood pressure, such as hypertension (high blood pressure) and hypotension (low blood pressure), significantly affect human health. Understanding these conditions' classifications, causes, and symptoms is essential for effective management and treatment.
    Hypertension (High blood pressure)
    Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
    2.2K
    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
    718
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    1.6K